Administrative Databases and Diagnostic Therapeutic and Assistance Paths -PDTA- in the Monitoring Treatment of Rheumatoid Arthritis: The Experience of ATS Pavia.

Autor: Bruno, Giacomo M, Valentino, Maria Chiara, Brunetti, Alessandra, Matteo, Sergio Di, Begovic, Ivan, Croce, Edoardo, Sakellariou, Garifallia, Bugatti, Serena, Perotti, Pietro, Vecchio, Silvia, Migliazza, Simona, Langella, Roberto, Colombo, Giorgio L
Předmět:
Zdroj: Pragmatic & Observational Research; Apr2023, Vol. 14, p29-38, 10p
Abstrakt: Objective was to evaluate the adherence of the drugs of interest, by utilizing specific indicators (MPR).Results: A total of 145 patients were analyzed. Among enrolled patients, 26.9% of users were treated with a biosimilar drug, while 73.1% with a biologic originator. Adherence is higher if it is considered the population treated with biosimilar drugs (82.1%). Total cost (including drug prescriptions, hospitalizations, outpatient services, tests for any cause) during the observation period of 1 year is 14,274.08. 87.7% of the total is attributable to drugs. Non-hospitalized patients are the least expensive, whether they were treated with biologics or biosimilars.Conclusion: In our sample, biosimilar drugs tend to be underused: the treatment of a patient with a chronic autoimmune disease is a clinical process that involves many health professionals, and a criticality could also derive from the difficult communication between the various professional figures who get involved with the whole patient treatment. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje